No Cover Image

Journal article 397 views

Evaluation of nasal epithelium sampling as a tool in the preclinical development of siRNA-based therapeutics for asthma / Gareth D Healey; Neil Evans; Julian M Hopkin; Gwyneth Davies; William Walker

Journal of Cellular and Molecular Medicine, Volume: 17, Issue: 3, Pages: 356 - 364

Swansea University Author: Walker, William

Full text not available from this repository: check for access using links below.

Check full text

DOI (Published version): 10.1111/jcmm.12014

Abstract

The development of siRNA-based asthma therapeutics is currently hampered by a paucity of relevant biomarkers and the need to ascertain tissue-specific gene targeting in the context of active disease. Epithelial STAT6 expression is fundamental to asthma pathogenesis in which inflammatory changes are...

Full description

Published in: Journal of Cellular and Molecular Medicine
ISSN: 15821838
Published: 2013
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa13398
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract: The development of siRNA-based asthma therapeutics is currently hampered by a paucity of relevant biomarkers and the need to ascertain tissue-specific gene targeting in the context of active disease. Epithelial STAT6 expression is fundamental to asthma pathogenesis in which inflammatory changes are found throughout the respiratory tract. Therefore, to improve preclinical evaluation, we tested the efficacy of STAT6-targetting siRNA within nasal epithelial cells (NEC’s) obtained from asthmatic and non-asthmatic donors. STAT6 expression was invariant in both donor groups and amenable to suppression by siRNA treatment. In addition, STAT6 mRNA was also suppressible by apically delivered siRNA treatment in comparative differentiated nasal epithelial cell-line monolayer cultures. Analysis of donor NEC’s showed consistent elevation of CCL26 (eotaxin-3) mRNA within the asthmatic group suggesting potential as a relevant biomarker. Furthermore, targeting of STAT6 with siRNA attenuated IL-13-driven CCL26 expression in these cells, pointing to the utility of this approach in preclinical testing. Finally, siRNA-mediated suppression of STAT6 was independent of donor disease phenotype or epithelial cell differentiation status, signifying therapeutic potential.
Item Description: In press, accepted 28/11/12
Keywords: Asthma, biomarker, CCL26, nasal epithelium, preclinical, siRNA, STAT6
College: Swansea University Medical School
Issue: 3
Start Page: 356
End Page: 364